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Terminal deoxynucleotidyl transferase (TdT)  1 is currently thought to be a T- 
cell-specific enzyme. The enzyme was initially purified from calf thymus (1) and 
it catalyzes the polymerization of deoxynucleotides in the presence of a primer 
(1-3).  Despite  extensive  research of the  in  vitro  catalytic properties  of the 
enzyme (4,  5), the in vivo function of the enzyme is unknown. In a  variety of 
species that have been examined (6-8), TdT is only found in thymocytes or bone 
marrow cells,  suggesting  a  specific T-cell  association.  In  rats,  TdT  activity 
appears  to  be  restricted  to  the  major  thymocyte subpepulation,  which  is 
characterized by small size, cortisone sensitivity, and moderate density (7, 9). 
Based on these data,  it  has  been suggested that  TdT functions in the early 
stages of T-cell development (9). TdT is also found in the peripheral sites of 
leukemic cell infiltration in T-cell leukemias of several species (10-16).  These 
data have suggested that the expression of TdT may be a characteristic of T-cell 
leukemias and may reflect a block in differentiation (7). 
Although considerable research has dealt with the distribution of TdT in T- 
cell subpopulations,  little is  known of the molecular mechanisms controlling 
either TdT expression or thymocyte differentiation. In murine thymocytes two 
TdT activities are separable by phosphocellulose chromatography (peak I and 
peak II), which have comparable in vitro primer and substrate requirements, 
and which appear  to be serologically identical  (8,  16,  17). However, the two 
enzyme activities  have  very distinct  biological properties  in  that  in  certain 
strains of mice (NIH Swiss and AKR), peak II activity is rapidly lost with age, 
whereas peak II activity in other strains  (C57BL/6)  does not decline until at 
least 6 mo of age. In all strains examined, peak I activity is comparable and 
retained  with  age  (16). More  interestingly,  however,  peak  I  in  all  strains 
examined is uniquely associated with leukemic T cells infiltrating peripheral 
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1Abbreviations  used  in  this  paper:  BSa,  bovine  serum  albumin;  dGTP,  deoxyguanosine 
5'-triphosphate; TdT,  terminal deoxynucleotidyl transferase; TEM, a buffer of 0.05 M Tris,  pH 
7.8, 1 mM of EDTA, and 1 mM of 2-mercaptoethanol; TEM-G, TEM plus 20% glycerol. 
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lymphoid tissues  (16). In mice, TdT is  also thought to be  associated with a 
prothymocyte population in the bone marrow. This hypothesis was suggested 
by the observation that TdT-containing bone marrow cells could be lysed with 
antisera against theta after treatment in vitro with thymopoietin (18). These 
experiments, however, were compromised by the extremely low activity of TdT 
normally detectable in whole bone marrow. More recently, it has been shown 
that TdT is associated with a unique bone marrow subpopulation separable by 
bovine serum albumin (BSA) gradient centrifugation (19). The enzyme-specific 
activity of TdT in this subpopulation, which comprises only 1-5% of the total 
bone marrow cells, is comparable to that of thymocytes. Interestingly, only low 
levels of TdT were present in this bone marrow fraction of NIH Swiss nude 
mice, suggesting that TdT expression in bone marrow is possibly regulated by 
thymic factors. In the present experiments, we have extended these observa- 
tions and examined the ability of thymic hormones to induce TdT in athymic 
mice. The results demonstrate that thymosin fraction 5 can induce the de novo 
appearance of TdT in vitro in specific bone marrow subpopulations of athymic 
mice. 
Materials and Methods 
Mice.  C57BL/6 and NIH Swiss nu/nu specific pathogen-free mice used in these experiments 
were obtained from the Frederick Cancer Research Center Animal Breeding Section, Frederick, 
Md. Ages of the different mice are given in the Results section. 
Cell Fraetionation.  Preparation  of cell  suspensions  from  spleens,  lymph  nodes,  and  bone 
marrows  has  been  previously  described  (16).  The  method  of Raidt  et  al.  (20)  was  used  to 
fractionate the different cell suspensions.  Four layers of cells were formed at the interfaces of the 
discontinuous  BSA gradient:  fraction A, between 10 and 23% BSA; fraction B, between 23 and 
26%; fraction C, between 26 and 29%;  and fraction D, between 29 and 33% BSA. BSA (Path-O- 
Cyte  5,  lots  25  and  26)  was  obtained  from  Miles  Laboratories  Inc.,  Miles  Research  Products 
(Elkhart,  Ind.).  Fractionated cells were washed three times in Ham's F-12  medium. 
Enzyme Preparation.  Approximately 1 x  los cells from the different layers were resuspended 
in  a  1-ml buffer  solution  of 0.05  M  Tris,  pH  7.8,  1 mM EDTA,  and  1 mM 2-mercaptoethanol 
(TEM), and frozen-thawed.  Immediately after thawing, 3 ml of TEM buffer containing 2 M KC1 
and 0.66% Triton were added. The homogenate was stirred at 4°C for 2-4 h and dialyzed overnight 
against 100 vol of TEM buffer containing 50 mM KC1. 
The dialyzed solution was centrifuged at 100,000 g  for 60 rain, and the supernate was loaded on 
a  1 x  15-cm Pll phosphocellulose column (Whatman,  Inc., Clifton, N. J.) and equilibrated with 
50 mM KCI in TEM plus 20% glycerol (TEM-G). After loading, the column was washed with 15 ml 
of TEM-G, 50 mM KC1, and then eluted with a linear gradient (50 ml) of 0.05-0.75 M KC1 in TEM- 
G buffer. The flow rate of the column was 1-1.2 ml/10 rain, and 1.0-ml fractions were collected. 
TdT  Assay.  The  TdT  assay  was  adapted  from  Kung  et  al.  (8)  and  has  been  previously 
described. One unit of enzyme activity was defined as the amount catalyzing the incorporation of 
1 pmol of deoxyguanosine  5'-triphosphate  (dGTP)  into  acid-insoluble  material  per h.  Specific 
activity was calculated from the total enzyme activity recovered from phosphocellulose per l0  s 
nucleated viable cells. Under the conditions of the assay, the lowest detectable activity is ~ 0.05 
pmol of dGTP incorporated. 
Thymectomy.  3-wk-old C57BL/6 mice were thymectomized using the procedure of Sjodin et al. 
(21). 
Thymosin Treatment In Vivo.  Thymosin fraction 5 (lot BPM 390),  and spleen fraction 5 (lot 
307), purified as previously described (22, 23), were resuspended in saline solution at a concentra- 
tion of 500  ~g/ml. 
10 daily injections of 100 pg were given intraperitoneally to 6-wk-old NIH Swiss nu/nu or to 15- 
wk-old C57BL/6 mice, which had been thymectomized at 3 wk of age. Animals were sacrificed 24 
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For the  in vitro induction experiments,  cells were washed three times after BSA gradient 
fractionation in Ham's F-12 medium containing 100 U/ml penicillin, 100 ~g/ml streptomycin, and 
10 ~g/ml gentamycin. After washing, cell concentrations were adjusted to 1 x  108 cells/ml in the 
same medium.  The different fractions were plated at  1  x  108 cells/dish in 10 ml of Ham's F-12 
medium containing antibiotics, 5% fetal bovine serum (Flow Laboratories, Inc., Rockville, Md.), 
and different concentrations of thymosin or spleen fraction 5. After incubation for various periods 
of time, cells were collected, washed twice with Ham's F-12, and extracted as previously described 
for TdT activity (16). 
Actinomycin-D  Treatment  and [3H]Uridine Labeling.  Actinomycin  D,  at  0.5  ~g/ml,  was 
incubated for 12 h in the presence of thymosin and fraction B from the bone marrow of NIH Swiss 
nu/nu mice to study their effect on TdT induction. To follow the effect of actinomycin D on RNA 
synthesis, cells were labeled with 10 ~Ci/ml of [aH]uridine for the last 90 min of incubation. 
Results 
The distribution of TdT in BSA gradient-fractionated bone marrow cells from 
various strains of mice is shown in Table I. As previously reported (19), and as 
is  illustrated here by the results with NIH Swiss and C57BL/6  mice, TdT is 
primarily associated with cells of the A fraction. The fact that the peak II TdT 
activity is lost early in life in NIH Swiss mice is also consistent with previous 
results (16) that there is a difference in enzyme expression between these two 
strains.  Also shown in Table  I  are the results obtained with BSA gradient- 
fractionated lymphoid tissues of NIH Swiss nude mice. These mice had only low 
levels of TdT in  the bone marrow fraction A  cells and no TdT activity was 
detectable in gradient-fractionated cells of either spleen or lymph nodes. These 
results suggest that either the thymus or thymic factors are required for TdT 
expression in the bone marrow. 
To examine further the influence of the thymus on TdT expression in the 
bone marrow, 3-wk-old C57BL/6 mice were thymectomized and TdT expression 
in bone marrow was followed with time after thymectomy. As is illustrated in 
Table II, thymectomy had a  significant influence on TdT activity in the bone 
marrow. By 8 wk after thymectomy, >95% of the peak II activity was lost and 
only ---35% of the peak I activity remained. By 16 wk after thymectomy, >95% 
of the total TdT activity was lost.  At no time after thymectomy was enzyme 
activity detected in  either  spleen  or  lymph nodes  (data  not  shown).  These 
results are therefore consistent with the results from nude mice in suggesting a 
role for the thymus in the regulation of TdT in the bone marrow. 
It has been previously demonstrated that T-cell functions can be enhanced by 
the  administration  of thymus  extracts  (24-27).  We  therefore examined the 
ability of thymosin fraction 5,  a  partially purified thymus extract, to restore 
TdT expression in bone marrow of thymectomized and nude mice. As is shown 
in Table III,  10 daily injections of 100  p~g of thymosin fraction 5 significantly 
increased TdT  activity  in  bone  marrow  fraction  A  cells  of both  nude  and 
thymectomized mice, which is consistent with the normal cellular distribution 
of TdT activity. The effect was specific for thymosin fraction 5 in that neither 
spleen  fraction 5  nor  saline  had  significant  effects.  Interestingly,  thymosin 
treatment of nude mice resulted primarily in the appearance of peak I activity 
at a specific activity comparable to nu/+ littermates and little peak II activity, 
in a manner consistent with the strain-dependent differences normally seen in 
the  two  activities  (16). However, both  TdT peaks  I  and  II  were  induced in NELSON  H.  PAZMII~O,  JAMES  N.  IHLE,  AND  ALLAN  L.  GOLDSTEIN  711 
TABLE  I 
Distribution of Terminal  Transferase Activity in BSA-Fractionated  Lymphoid Tissues 
from Normal and Athymic Mice 
BSA fraction 
A  B  C  D 
I  II  I  II  I  II  I  II 
NIH  Swiss  nu/+  145"  -*  6  -  1  -  -  - 
bone marrow 
C57BL/6  bone  225  1,364  15  180  -  8  -  15 
marrow 
NIH  Swiss  nu/nu  16  -  3  -  1  -  -  - 
bone marrow 
NIH  Swiss  nu/nu  ........ 
spleen 
NIH  Swiss  nu/nu  ........ 
lymph nodes 
* Picomoles of  [3H]dGTP incorporated per  h per 10  8  cells.  Mice used  were 6 wk of  age. 
Not detectable. 
TABLE  II 
TdT Activity in Thymectomized  C57BL/6 Mice* 
Weeks 
alter  thy- 
mectomy 
Bone marrow fractions 
A  B  C  D 
I  II  I  II  I  II  I  II 
0  195*  1,310  41  110  2  6  -§  - 
1  240  360  70  130  5  5  7  10 
8  71  -  15  5  3  -  -  - 
16  11  ....... 
* C57BL/6  mice  thymectomized  at  3  wk  of  age  and  assayed  at  various  times  after 
thymectomy. 
$ Picomoles of [3H]dGTP incorporated per h  per 108 cells. 
§ Not detectable. 
thymectomized C57BL/6 mice at specific activities comparable to those seen in 
normal thymic-bearing controls. No TdT activity was detectable in fractionated 
cells  from  either  spleen  or  lymph  nodes  of thymosin-treated  mice  (data  not 
shown). 
The results of in vivo thymosin treatment suggested that thymosin fraction 5 
can promote TdT expression in bone marrow.  However, it was not possible to 
differentiate between a direct inductive event or a secondary effect on differen- 
tiation. We therefore examined the ability of thymosin fraction 5 to induce TdT 
in vitro in fractionated bone marrow and spleen cells from NIH Swiss nude or 
thymectomized C57BL/6 mice. The results obtained with NIH Swiss nude mice 
are  shown in Table IV.  When fractionated spleen or bone marrow cells were 
treated  with  25  ng/ml  of thymosin  fraction  5  for  18  h,  TdT  was  specifically 712  TERMINAL  DEOXYNUCLEOTIDYL  TRANSFERASE  INDUCTION 
TABLE  HI 
In Vivo Reconstitution of TdT Activity in Bone Marrow Cells from Nude and 
Thymectomized Mice with Thymosin Fraction 5* 
Bone marrow  fractionated  on BSA 
NIH Swiss  Nu/Nu  Thymectomized C57BL/6 
A  B  C  D  A  B  C  D 
I  II  I  II  I  II  I  II  I  II  I  II  I  II  I  II 
Thymosin fraction  210  3  32  -$  3  -  2  -  141  916  24  69  5  10 
5 
Spleen fraction 5  18  -  10  -  3  21  136  2  7  5  3  3 
Saline  22  4  9  1  12  2  4 
*  NIH  Swiss nude and thymectomized C57BL/6 were given 10 daily injections of spleen fraction 5, 
thymosin fraction 5, or saline, i.p.;  24 h  after the last injection, the mice were sacrificed and TdT 
was isolated as described in Materials and Methods. 
$ Not detectable. 
TABLE  IV 
In Vitro Induction  of TdT in Fractionated  Spleen  and Bone Marrow 
Cells from NIH Swiss nu/nu Mice by Thymosin Treatment* 
Treatment 
BSA fraction 
A  B  C  D 
Saline  Spleen  -  *  -  -  - 
Bone  marrow  2.5  0.9  -  1.0 
Spleen  frac-  Spleen  .... 
tion  5  Bone marrow  13.4  -  -  - 
Thymosin  Spleen  8.1  -  -  - 
fraction  5  Bone marrow  2.0  131  -  - 
*  Values  for peak I  activity only.  Incubation  was for  18  h  with  75  ng/ml  of 
thymosin or spleen fraction 5. 
$ Not detectable. 
induced in fraction B  bone marrow cells.  Moreover, the specific activity of the 
enzyme was ~ 60% of the value found after in vivo thymosin treatment,  and it 
had the characteristics of peak I activity.  The in vitro induction was specific in 
that neither spleen fraction 5 nor saline significantly increased enzyme activity, 
and activity was not induced in either fractionated spleen cells or other fractions 
of  bone  marrow  cells.  Comparable  results  were  obtained  for  the  in  vitro 
induction  of TdT  in  bone  marrow  cells  from  thymectomized  C57BL/6  mice 
(Table  V).  As  above,  thymosin  fraction  5  specifically  induced  TdT in  the  B- 
fraction cells.  In contrast to the results with NIH Swiss nude mice,  however, 
both peaks I and II were induced at ratios comparable to those normally found, 
and at a specific activity of ~ 50% of the normal bone marrow fraction A  cells. 
Spleen fraction 5 had only a minimal inductive effect and yielded -  10% of the 
specific  activity  found with  thymosin  fraction  5.  These  results  demonstrate, 
therefore,  that  thymosin  fraction  5  can  directly  induce  TdT  in  vitro  in bone 
marrow cells from athymic mice. NELSON  H.  PAZMII~O,  JAMES  N.  IHLE,  AND  ALLAN  L.  GOLDSTEIN  713 
TABLE  V 
In Vitro Induction of TdT in Fractionated  Spleen and Bone Marrow  Cells from 
Thymectomized C57BL/6 Mice by Thymosin Treatment 
BSA fraction 
Bone marrow  Spleen 
A  B  A  B 
I  II  I  II  I  II  I  II 
Saline  19  -  *  8  .... 
Spleen  frac-  25  4  35  71  -  -  - 
tion 5 
Thymosin  21  10  91  673  -  -  - 
fraction  5 
•  Not detectable. 
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Fro.  1.  Concentration and time dependence of the induction of TdT by thymosin fraction 
5. NIH Swiss nu/nu bone marrow cells were fractionated on BSA gradients and the B layer 
was used in induction experiments. (A) The cells were treated with varying concentrations 
of thymosin fraction 5  for  12  h  and then extracted; TdT  activity was determined after 
phosphocellulose chromatography.  (B)  Cell  suspensions were treated  with  25  ng/ml of 
thymosin fraction 5 in the presence (O) or absence (O) of 0.5/~g/ml of actinomycin D. At 
the indicated intervals, samples of the cells were collected, and extracted; TdT activity was 
determined after phosphocellulose  chromatography. Only TdT peak I was detected in these 
samples. 
The concentration  dependence for the induction  of TdT in fraction B, nude 
bone marrow cells by thymosin fraction 5 is shown in Fig.  1 A. Concentrations 
as low as 3 ng/ml had a significant effect, and ~ 30 ng/ml was optimal. At higher 
concentrations,  there was a  significant inhibitory effect which was not associ- 
ated with cell death (data not shown). The kinetics of induction using 25 ng/ml 
are shown in Fig.  1 B. As illustrated by the results, induction in vitro is rapid, 
and within 2 h  a  significant increase in TdT is evident.  By 4-6 h  the cells are 
fully  induced,  and  enzyme  activity  remains  constant  for  up  to  24  h.  Also 714  TERMINAL  DEOXYNUCLEOTIDYL  TRANSFERASE  INDUCTION 
illustrated in Fig. 1B are the results obtained at 12 h in the presence of 0.5 P4g/ 
ml of actinomycin D.  Under these conditions,  >95% of the RNA synthesis is 
inhibited (data not shown), as is the induction of TdT. Taken together, these 
results suggest that thymosin fraction 5 induction of TdT is comparable to the 
pattern of induction observed for other enzymes in response to  specific hor- 
mones. 
Discussion 
The results clearly demonstrate that TdT expression in the bone marrow is 
dependent upon the presence of a thymus, and that TdT can be induced in the 
bone marrow of athymic mice both in vivo and in vitro ai~r treatment with 
thymosin fraction 5. An important role for the thymus in TdT expression had 
been previously suggested based on the observation that NIH Swiss nude mice 
had only low levels of TdT in fractionated bone marrow cells (19). We tested this 
hypothesis further by examining fractionated bone marrow from thymectomized 
mice for TdT expression. As the results illustrated, thymectomy had a profound 
effect on TdT expression in the bone marrow of C57BL/6 mice, so that by 16 wk 
after thymectomy, <5%  of the initial  activity was detectable.  Interestingly, 
there was a differential rate of loss of peak I and peak II activities, recalling the 
loss of activity seen during aging (16). In particular, peak II was lost rapidly 
after  thymectomy,  whereas  peak  I  was  lost  at  a  much  slower  rate.  This 
observation, in addition to the other age, tumor, and strain differences previ- 
ously noted (16, 19), suggests that peak I and peak II activities are biologically 
different and may have distinct functional properties.  However, whether the 
two peaks of activity are unique enzymes or one enzyme with two forms is not 
known, since the data are also consistent with a peak II to peak I conversion. 
Treatment of either NIH Swiss nude mice or thymectomized C57BL/6 mice 
with thymosin fraction 5 induced, in vivo, the expression of TdT in fractionated 
bone marrow cells. This induction was specific to thymosin fraction 5 in that a 
hormone preparation comparable to thymosin in its preparation but isolated 
from calf spleen had no effect, nor did saline. The induction of TdT in vivo was 
striking since the specific activity of the enzyme was comparable to that seen in 
normal, thymic-bearing controls and since the enzyme was primarily associated 
with the A fraction of BSA-gradient fractionated cells. In addition, the ratios of 
peak  I  and peak II were identical to  the thymic-bearing controls,  and they 
illustrated~the  strain-dependent  differences normally  observed.  These  data 
suggest that the differences seen in peak I and II expression are probably not 
related to differences in the factors required for induction, but are rather at the 
cellular level of enzyme expression as discussed below. 
Although thymosin fraction 5 clearly induced TdT expression in vivo, such 
experiments can not distinguish between a direct inductive event or a promotion 
of differentiation, which has as a secondary consequence the expression of TdT. 
We therefore examined the ability of thymosin fraction 5 to induce TdT in vitro 
in  fractionated  bone  marrow  cells  from  athymic  mice.  The  results  clearly 
demonstrated that thymosin fraction 5 can induce enzyme activity in vitro very 
effectively, suggesting a direct hormone-like effect on TdT expression. As above, 
the  effect was  specific  in  that  neither  spleen  fraction  5  nor  saline  had  a NELSON  H.  PAZMII~O,  JAMES  N.  IHLE,  AND  ALLAN  L.  GOLDSTEIN  715 
comparable effect. In contrast to the above results, however, TdT was primarily 
induced in the B fraction of cells from BSA gradients, whereas in vivo TdT is 
primarily associated with the A fraction. These dam might be best interpreted 
to suggest that the B fraction contains the stem cell for the TdT-positive A- 
fraction cells. Experiments are currently in progress to examine this question 
by determining the density distribution of TdT-expressing cells after in vitro 
induction. Previous reports have demonstrated that fraction B can effect thymic 
reconstitution of irradiated mice, although the A fraction also had more limited 
capabilities (28). Whether or not the ability to express TdT and to reconstitute 
the thymus resides in the same stem-cell populations is not known. However, 
the observation that the B-fraction cells from spleens can effect thymic reconsti- 
tution, but as shown here, are not inducible for TdT, suggests that these two 
functions may belong to different cell populations. 
In a  manner similar to the results in vivo,  induction of TdT in vitro with 
thymosin fraction 5 resulted in only peak I activity in cells from NIH Swiss 
nude mice, and peaks I and II in cells from thymectomized  C57BL/6 mice. These 
results clearly demonstrate that the difference between peaks I  and II  is  a 
strain-dependent difference in the cellular response to thymic factors, rather 
than a difference in the requisite hormones. In particular, it was conceivable 
that  peak I  and peak  II were regulated by different hormones and that in 
certain strains, the hormone-inducing peak II is lost early. As is shown here, 
however, a thymic hormone preparation capable of inducing peak II activity in 
C57BL/6 bone marrow cells did not induce peak II activity in NIH Swiss nude 
bone marrow. Thus, it is still unknown what cellular factors are involved in the 
differences observed here. 
The in vitro induction of TdT demonstrated here appears to be comparable to 
many classical examples of hormone induction of enzymes. The concentrations 
ofthymosin  required are extremely  low (25 ng/ml) and well within physiological 
levels.  Comparably low levels of thymosin have been shown to induce them 
antigen expression (26). It should also be noted that since thymosin fraction 5 
contains several peptides (29), the actual concentration of the active fraction, 
assuming a single peptide is involved, may be below 1 ng/ml. The concentration 
dependence for induction shows a marked inhibition at high thymosin concen- 
trations. This effect does not appear to be the result of cell killing, but it may be 
related to the ability of thymosin to promote a variety of thymic functions (22, 
23,  25-27, 29). Thus,  if several  hormonally active  peptides  are  present  in 
thymosin, competition may exist in promoting differentiation. For example, in 
preliminary experiments we have examined the effect of thymosin alpha-1 on 
the induction of TdT in vitro, and we found that it does not induce the enzyme. 
Thymosin alpha-l, which is the first thymic peptide hormone sequenced, has a 
mol wt of 3,100 and is  10-100 times as  active as fraction 5 in  a  number of 
thymosin assays  (29). In this regard, it should also be noted that thymosin 
fraction 5 can induce expression of theta in nude mice, and it now becomes 
imperative to know whether the same or different thymic factors are involved 
in TdT and theta expression. Clearly, these phenomena can only be resolved by 
examining the effects of purified peptides from thymosin. 
The time course for induction of TdT expression in vitro is extremely rapid 716  TERMINAL  DEOXYNUCLEOTIDYL  TRANSFERASE  INDUCTION 
and  comparable  to  the  patterns  observed  in  vitro  with  other  enzymes  and 
hormones.  Interestingly,  induction  is  complete  within  6  h,  and  the  level of 
enzyme activity is maintained relatively constant for up to 24 h. Whether or not 
the maintenance of enzyme activity requires the continued presence ofthymosin 
fraction 5 is presently under investigation.  The results also demonstrate that 
the induction of TdT is completely inhibited by actinomycin D, suggesting that 
RNA synthesis is required,  and that the expression of TdT requires de novo 
synthesis of the enzyme. Clearly, however, continued efforts will be required to 
establish this point definitively. Nevertheless,  our results demonstrate that a 
unique T-cell enzyme can be induced in vitro with thymic hormones. 
Summary 
Terminal  deoxynucleotidyl  transferase  (TdT)  expression  in  bovine  serum 
albumin  (BSA) gradient-fractionated bone marrow cells was examined in NIH 
Swiss nu/nu and thymectomized C57BL/6 mice. In nude mice, TdT levels were 
approximately  10% of those of thymus-bearing  littermates.  In C57BL/6 mice, 
thymectomy caused a time-dependent loss of TdT activity in bone marrow cells. 
To  determine  whether  or  not  the  apparent  thymic  requirement  for  TdT 
expression in bone marrow was mediated by thymic hormones,  we examined 
the  effects of thymosin  fraction  5.  Treatment  of either  NIH Swiss nu/nu  or 
thymectomized  C57BL/6 mice with thymosin fraction  5 restored the levels of 
TdT  activity  in  BSA  gradient-fractionated  bone  marrow  cells  to  normal. 
Moreover, treatment of BSA gradient-fractionated bone marrow cells from NIH 
Swiss nu/nu  or thymectomized C57BL/6 mice in tissue culture with thymosin 
fraction 5 induced TdT expression. In tissue culture, TdT induction was optimal 
with  25  ng/ml  of thymosin  fraction  5,  it  occurred  within  6  h,  and  it  was 
completely inhibited by actinomycin D. The effect was specific in that neither 
control nor spleen fraction 5-treated cells were induced to express TdT. These 
data demonstrate that TdT expression in bone marrow cells is under the direct 
control of thymic polypeptide hormones. 
Received for publication 13 September 1977. 
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